

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12Q 1/68, G06F 17/30</p>	<p>A1</p>	<p>(11) International Publication Number: WO 00/17392 (43) International Publication Date: 30 March 2000 (30.03.00)</p>
<p>(21) International Application Number: PCT/GB99/03057 (22) International Filing Date: 15 September 1999 (15.09.99) (30) Priority Data: 9820338.3 19 September 1998 (19.09.98) GB (71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): MORTEN, John, Edward, Norris [GB/GB]; Alderley Park, Macclefield, Cheshire SK10 4TG (GB). (74) Agent: GILES, Allen, Frank; AstraZeneca PLC, Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: POLYMORPHISMS IN THE HUMAN VCAM-1 GENE, SUITABLE FOR DIAGNOSIS AND TREATMENT OF VCAM-1 LIGAND MEDIATED DISEASES</p> <p>(57) Abstract</p> <p>This invention relates to polymorphisms in the human Vascular Cell Adhesion Molecule-1 (VCAM-1) gene, in particular at one or more of positions 278, 647, 707, 748, 829 and 1467 in the VCAM-1 gene as defined by the positions in EMBL ACCESSION NO. M92431. The invention also relates to methods and materials for analysing allelic variation in the VCAM-1 gene, and to the use of VCAM-1 polymorphism in the diagnosis and treatment of VCAM-1 ligand mediated diseases such as multiple sclerosis, rheumatoid arthritis, atherosclerosis and allergic asthma.</p>		